New hope for tough psoriasis spots: tildrakizumab under the microscope
NCT ID NCT05938361
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how well tildrakizumab works for psoriasis in areas that are often hard to treat, like the scalp, nails, genitals, and palms. About 120 adults with moderate to severe psoriasis will receive tildrakizumab and be followed for up to 52 weeks. The goal is to see if the drug improves these stubborn spots and overall quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tildrakizumab (an injected antibody that blocks IL-23 to reduce inflammation)
- What this could lead to
- If successful, this could show that tildrakizumab is a good option for treating psoriasis in areas that are usually hard to manage, like the scalp, nails, genitals, and palms.
- What could go wrong
- This is a single-arm study with no placebo group, so results may be less reliable. It is also relatively small (120 people) and only follows participants for 52 weeks, so long-term effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS GENITAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Service de Dermatologie- Hopital Saint Joseph
Paris, 75014, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.